scholarly journals Serum carcinoembryonic antigen as a tumour marker in patients with endometrial cancer

2016 ◽  
Vol 23 (5) ◽  
pp. 439 ◽  
Author(s):  
Y. Hashiguchi ◽  
M. Kasai ◽  
T. Fukuda ◽  
T. Ichimura ◽  
T. Yasui ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Carcinoembryonic Antigen ◽  
Menopausal Status ◽  
Elevated Serum ◽  
Case Series ◽  
Myometrial Invasion ◽  
Tumour Markers ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background No potential tumour markers have been validated for prognosis in endometrial cancer. However, carcinoembryonic antigen (cea) is one of the most widely used tumour markers in various types of cancer. Although cea expression in endometrial cancer has been investigated, its prognostic value remains controversial, and no studies have investigated serum cea levels in large case series. In the present study, we investigated diagnostic and prognostic applications of serum cea for endometrial cancer.Methods This prospective study was approved by our Institutional Review Board. Between January 2006 and December 2012, serum cea was measured prospectively in 215 patients with endometrial cancer and was subsequently measured during treatment and at scheduled follow-up examinations in patients with elevated basely ne serum cea.Results During the study period, 215 patients (142 stage i, 19 stage ii, 32 stage iii, 22 stage iv) were treated for endometrial cancer. By the time of last follow-up, 52 had relapsed (24.2%), and the median follow-up duration was 45 months (range: 1–95 months). Elevated serum cea was identified in 25 patients (11.6%) and was associated with histologic type (p = 0.04), histologic grade (p = 0.03), and myometrial invasion depth (p = 0.01). Elevated serum cea was not related to clinical stage, lymph node metastasis, distant metastasis, age, menopausal status, or body mass index. Relapse of disease was related to elevated serum cea (p = 0.006).Conclusions Serum cea is a potential prognostic indicator for endometrial cancer.

Pseudopsammomatous meningioma with elevated serum carcinoembryonic antigen: a true secretory meningioma

1991 ◽  
Vol 74 (1) ◽  
pp. 129-132 ◽  
Author(s):  
David N. Louis ◽  
Allan J. Hamilton ◽  
Raymond A. Sobel ◽  
Robert G. Ojemann
Keyword(s):  
Carcinoembryonic Antigen ◽  
Elevated Serum ◽  
Immunohistochemical Analysis ◽  
Intracranial Tumor ◽  
Vascular Pattern ◽  
Rare Occurrence ◽  
Content Type ◽  
Secretory Meningioma ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

✓ A sphenoid-wing meningioma in a 60-year-old woman was accompanied by elevated serum carcinoembryonic antigen (CEA) levels, which returned to normal after removal of the tumor. Light microscopic examination revealed a secretory meningioma containing numerous pseudopsammoma bodies and a prominent vascular pattern. Immunohistochemical analysis showed the tumor cells and pseudopsammoma bodies to be CEA-positive. This case illustrates the possibility that secretory meningioma may be associated with clinically detectable secretion of CEA. The report also documents the rare occurrence of elevated serum CEA in a primary benign intracranial tumor.

Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis

Rheumatology ◽  
2021 ◽  
Author(s):  
Dingxian Zhu ◽  
Jianjun Qiao ◽  
Shunli Tang ◽  
Yunlei Pan ◽  
Sheng Li ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Carcinoembryonic Antigen ◽  
Elevated Serum ◽  
Multivariate Logistic Regression Analysis ◽  
Laboratory Findings ◽  
Serum Carcinoembryonic Antigen ◽  
Lower Lung ◽  
Serum Cea ◽  
Lung Zone

Abstract Objectives The present study aimed to determine the correlation between serum carcinoembryonic antigen (CEA) level and the severity of interstitial lung disease (ILD) in clinically amyopathic DM (CADM) patients. Methods We performed a retrospective study including 41 Chinese CADM patients without malignancy. Serum CEA levels, clinical and laboratory findings were collected. Association tests between CEA levels and disease activity parameters were performed. Results Among the 41 patients, 16 (39.0%) developed rapidly progressive (RP)-ILD; of them, 14 (87.5%) had elevated serum CEA levels. Multivariate logistic regression analysis indicated that an elevated serum CEA level was an independent risk factor for RP-ILD. The incidence of elevated CEA level was significantly higher in patients with RP-ILD than in those without RP-ILD (87.5 vs 16.0%, P < 0.001). Furthermore, CEA levels were higher in patients with CADM with RP-ILD [26.87 (6.71) μg/l] than in those without RP-ILD [3.23 (0.64) μg/l] (P < 0.001). CEA levels in CADM patients were associated with the ferritin, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase levels, and CT scores of the lungs. Also, elevated CEA levels are related to the organizing pneumonia pattern and lower lung zone consolidation in high-resolution CT. Moreover, the cumulative survival rate was significantly lower (68.4 vs 31.6%, P < 0.001) in the group with a CEA level >8.75 μg/l than that in the group with a CEA level <8.75 μg/l. Conclusions An elevated serum CEA level is common in patients with CADM, and a higher serum CEA level is a powerful indicator of RP-ILD and poor prognosis in those patients.

Carcinoembryonic Antigen and Breast Carcinoma Antigen (CA 15.3) in Preoperative Staging and Postoperative Monitoring of Patients with Carcinoma of the Breast

1988 ◽  
Vol 3 (3) ◽  
pp. 165-171 ◽  
Author(s):  
Y.T. Omar ◽  
A.E. Behbehani ◽  
N. Al-Naqeeb ◽  
M.M. Motawy ◽  
M.O. Folldi ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Carcinoembryonic Antigen ◽  
Preoperative Staging ◽  
Elevated Serum ◽  
Stage Iv ◽  
Response To Therapy ◽  
Normal Range ◽  
Ca 15.3 ◽  
Serum Cea

Serum levels of carcinoembryonic antigen (CEA) and breast carcinoma antigen (CA 15.3) were determined in patients with breast carcinoma: in 129 before initial surgical or nonsurgical treatment and in 134 afterwards. Before any initial treatment, CEA was elevated in 15% of patients with Stage IV disease and CA 15.3 was high in 11% with Stage III and 48% with Stage IV. While monitoring management active disease was associated with elevated serum CEA in 66% of the patients, with elevated CA 15.3 in 73% and with at least one of the markers elevated in 86%. Both tests had high specificity (93% and 98%). The rise in serum CEA and, even more so, of serum CA 15.3 roughly paralleled the increase in bulk of the tumor: from locoregional disease through metastases to the lungs, bones, lungs with bones, and liver. Decreases in the levels of serum CEA and CA 15.3 reflected response to therapy, increases in the level of at least one marker - treatment failure, and levels fluctuating above the normal range indicated stationary disease. During follow-up, the predictive value of a negative test (levels within the normal range), suggesting that the patient might be free of disease, was 61% for CEA alone, 67% for CA 15.3 alone, and 80% for the two tests combined. We conclude that an elevated serum level of only one of the markers was useful for staging, implying advanced disease. Determination of both markers jointly was useful for monitoring the effectiveness of the therapy and for follow-up aimed at detection of relapse.

scholarly journals Clinical Significance of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels Before Surgery and During Postoperative Follow-Up in Colorectal Cancer

2018 ◽  
Vol 103 (7-8) ◽  
pp. 322-330
Author(s):  
Harunobu Sato ◽  
Yoshikazu Koide ◽  
Miho Shiota ◽  
Hiroshi Takahashi ◽  
Zenichi Morise ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Disease Free Survival ◽  
Carbohydrate Antigen ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Group A ◽  
Serum Cea ◽  
Group B

Objective: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most common colorectal cancer markers. We aimed to identify the appropriate clinical conditions for measuring serum CEA and CA19-9 levels before surgery and during follow-up. Methods: This study included 1275 colorectal cancer patients who were divided into 3 groups according to preoperative CEA levels (group A, ≤5 ng/mL; group B, >5–≤11 ng/mL; group C, >11 ng/mL). Each group was subdivided into 2 groups according to preoperative CA19-9 levels (cutoff level: ≤37 U/mL). Recurrence and survival rates were analyzed. Results: Recurrence rate, disease-free survival after curative surgery, and prognosis were significantly worse in group A and B patients with high CA19-9 levels. At recurrence, CEA levels showed a greater increase in group B and C patients; CA19-9 levels increased in group A patients with high CA19-9 levels. At recurrence, high serum CA19-9 levels were observed in group A patients with high preoperative serum CA19-9 levels, even if the serum CEA level did not increase. Preoperative CA19-9 levels could predict recurrence and prognosis in groups A and B. Conclusion: Periodic CA19-9 determination is useful for monitoring recurrence among group A patients with high CA19-9 levels.

Surveillance with Serial Serum Carcinoembryonic Levels Detect Colorectal Cancer Recurrences in Patients who are Initial Nonsecretors

2010 ◽  
Vol 76 (10) ◽  
pp. 1100-1103 ◽  
Author(s):  
Alicia Holt ◽  
Rebecca A. Nelson ◽  
Lily Lai
Keyword(s):  
Colorectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Retrospective Review ◽  
Stage I ◽  
Recurrent Colorectal Cancer ◽  
Serum Carcinoembryonic Antigen ◽  
Serial Serum ◽  
Resected Stage ◽  
Initial Resection

Serum carcinoembryonic antigen (CEA) levels, elevated in a subgroup of patients with colorectal cancer (CRC) at presentation, are serially followed as part of recommended surveillance after initial resection. The value of following serial CEA levels in patients who initially present with less than or normal levels of CEA (nonsecretors) is controversial. This study sought to determine the use of follow-up CEA levels in nonsecretors. A retrospective review was performed of patients with resected Stage I, II, and III CRC. We excluded patients who did not have a pretreatment CEA level, at least two follow-up CEA levels, or in whom CEA levels did not normalize after resection. The patients were grouped by initial CEA values: CEA 5 ng/mL or less (nonsecretors) and CEA 5 + ng/mL: (secretors). We identified 186 patients with CRC; 146 were initial nonsecretors. We identified 22 patients with recurrent colorectal cancer; 6 were secretors and 16 patients were nonsecretors. In the secretors group, CEA was elevated with recurrence in four (66%) of the patients. In the nonsecretors, CEA was elevated with recurrence in eight (50%) of the patients. In summary, many recurrences of CRC are marked by an elevation of CEA regardless of whether the patients initially presented as secretors or nonsecretors.

Secretory meningioma with elevated serum carcinoembryonic antigen level

1992 ◽  
Vol 37 (5) ◽  
pp. 415-418 ◽  
Author(s):  
Shigeru Tsunoda ◽  
Toshikazu Takeshima ◽  
Toshisuke Sakaki ◽  
Tetsuya Morimoto ◽  
Toru Hoshida ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Elevated Serum ◽  
Antigen Level ◽  
Secretory Meningioma ◽  
Serum Carcinoembryonic Antigen

Serum Levels of Carcinoembryonic Antigen, Gastrointestinal Cancer-Associated Antigen and Alphafetoprotein in Staging and Management of Patients with Advanced Carcinoma of the Stomach

1987 ◽  
Vol 2 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Janusz J. Szymendera ◽  
Andrzej W. Szawlowski ◽  
Marek P. Nowacki ◽  
Malgorzata Kowalska ◽  
Janina A. Kaminska ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Gastrointestinal Cancer ◽  
False Negative ◽  
Serum Levels ◽  
True Positive ◽  
True Negative ◽  
Carcinoma Of The Stomach ◽  
Joint Application ◽  
Serum Cea

Serum levels of carcinoembryonic antigen (CEA), gastrointestinal cancer-associated antigen (GICA or CA 19-9), and alphafetoprotein (AFP) were concurrently determined in patients with carcinoma of the stomach: in 84 preoperatively, and in 67 serially postoperatively. Before surgery, serum CEA gave information about the tumor load analogous to serum GICA in 69% of the patients: true-positive in 25% and false-negative in 43%; less information in 18% and more in 14%. The sensitivity of the test tended to be better in the more advanced stages, and was higher for CEA with GICA than for CEA alone or GICA alone. During follow-up, serum CEA gave information about the presence or absence of active disease analogous to serum GIC A in 78% of the patients: true-positive in 30%, true-negative in 36% and false-negative in 12%; less information in 9% and more in 13%. Neither test gave any false-positive indications. Sensitivity of the test rose from 67% for CEA alone and 60% for GICA alone to 81% for CEA with GICA. Serum AFP was elevated only preoperatively in 2% of patients. We conclude that joint application of CEA and GICA tests gave only slightly better preoperative sensitivity than CEA alone or GICA alone but proved fairly sensitive for postoperative follow-up of the patients. AFP was of little value for either purpose.

scholarly journals Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers

2017 ◽  
Vol 9 ◽  
pp. 1179299X1769014 ◽  
Author(s):  
Jingzhu Nan ◽  
Juan Li ◽  
Xiujuan Li ◽  
Guanghong Guo ◽  
Xinyu Wen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Carcinoembryonic Antigen ◽  
Youden Index ◽  
Rank Test ◽  
Prognostic Information ◽  
Treatment Implementation ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index. The data were analyzed by the Kaplan-Meier curves generated by the log-rank test and Cox multivariate analysis. Results: The overall survival rate for all the patients was 71.11%. The 3-year survival rate of patients with prostate, breast, gastric, and pancreatic cancers was 81.69%, 95.65%, 54.55%, and 51.61%, respectively. The 3-year survival rate showed significant statistical differences between patients with serum CEA levels <2.885 µg/L and those with serum CEA levels ⩾2.885 µg/L ( P < .001). The statistical differences of the 3-year survival rate also existed in the men ( P = .010) or women group ( P < .001), as well as in the 3 different types of cancer, which include breast cancer ( P = .025), gastric cancer ( P = .001), and pancreatic cancer ( P = .047). Conclusions: Serum CEA levels can provide additional prognostic information and may be useful in treatment implementation for patients with breast, gastric, or pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document